Acutus Medical, Inc. (AFIB)
| Previous close | 0.1721 |
| Open | 0.1730 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.1648 - 0.1748 |
| 52-week range | 0.1600 - 1.0900 |
| Volume | |
| Avg. volume | 2,351,885 |
| Market cap | 5.058M |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4100 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.50 |
Simply Wall St.Acutus Medical Full Year 2023 Earnings: US$0.41 loss per share (vs US$1.40 loss in FY 2022)
Acutus Medical ( NASDAQ:AFIB ) Full Year 2023 Results Key Financial Results Revenue: US$7.16m (down 56% from FY 2022...
GlobeNewswireAcutus Medical Reports Fourth Quarter and Full Year 2023 Financial Results
CARLSBAD, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB) today reported results for the fourth quarter and full year ended December 31,2023. Recent Highlights: Announced strategic realignment of resources and corporate restructuring on November 8, 2023 with the objective of optimizing financial position and maximizing free cash flow.The Continuing Operations focuses on the implementation of the business model to shift to solely support
- GlobeNewswire
Acutus Medical Reports Third Quarter 2023 Financial Results
CARLSBAD, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB) today reported results for the third quarter of 2023. Recent Highlights: Third quarter revenue of $5.2 million grew 44% year-over-year, led by strong growth in distribution revenue from sales of left-heart access products to MedtronicRegistered significant year-over-year reductions in both GAAP and non-GAAP operating expenses and cash burn, resulting from disciplined focus on expen
